Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

pSivida breaks BrachySil into Chinese market

This article was originally published in Clinica

Executive Summary

Australian bio-nanotech company pSivida has licensed its BrachySil technology to Beijing Med-Pharm for marketing and distribution in the Chinese market. Under the terms of the agreement, pSivida will pay its newly-appointed distributor upfront and milestone payments totalling more than $2m for clinical development of the product and securing regulatory approval, as well as royalties of up to 30% on future sales. The Perth-based company will retain the manufacturing rights to BrachySil.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT056835

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel